Wednesday, November 11, 2026
RBC Capital keeps Buy rating and $30 target on Ocular Therapeutix
RBC Capital repeated its Buy rating on Ocular Therapeutix and left its $30 price target unchanged. The call restates the firm's existing view on the stock.
Tuesday, November 10, 2026
HC Wainwright keeps Buy rating on Ocular Therapeutix, lifts target to $28
HC Wainwright & Co. reiterated its Buy rating on Ocular Therapeutix and raised its price target to $28. The change reflects the firm's updated view on the stock.
Monday, November 9, 2026
Ocular Therapeutix holds Q3 2026 earnings call
Ocular Therapeutix discussed its third-quarter 2026 results on an earnings call. The call covered the company's latest financial performance.
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
Ocular Therapeutix posts wider quarterly loss as revenue falls short
The biopharma company reported a third-quarter loss of $0.42 per share, missing the $0.36 loss analysts expected. Revenue of $12.874 million also came in below the $14.339 million estimate.
Monday, October 19, 2026
Needham Keeps Buy Rating on Ocular Therapeutix, $18 Target
Needham repeated its buy rating for Ocular Therapeutix and left its $18 price target unchanged. The analyst firm's stance on the eye care company stays the same.
Monday, October 12, 2026
UBS starts Ocular Therapeutix coverage with Buy rating, $14 price target
UBS began covering Ocular Therapeutix and gave the stock a Buy rating. The firm set a price target of $14 per share.
Wednesday, September 16, 2026
HC Wainwright Reaffirms Buy Rating on Ocular Therapeutix With $25 Target
HC Wainwright & Co. repeated its Buy rating on Ocular Therapeutix and kept its $25 price target unchanged. The analyst firm is maintaining its existing view of the stock.
Tuesday, September 15, 2026
Ocular Therapeutix finishes pre-NDA FDA meeting for AXPAXLI in wet AMD
Ocular Therapeutix said it completed a pre-NDA meeting with the FDA for AXPAXLI, its investigational treatment for wet age-related macular degeneration. The meeting is a step toward a possible marketing application for the product.
Frequently asked questions
What is the latest news on OCUL?
Nov 11, 2026: RBC Capital keeps Buy rating and $30 target on Ocular Therapeutix (Fiscal.ai) · Nov 10, 2026: HC Wainwright keeps Buy rating on Ocular Therapeutix, lifts target to $28 (Benzinga) · Nov 9, 2026: Ocular Therapeutix holds Q3 2026 earnings call (Benzinga)
What has OCUL filed with the SEC recently?
Nov 9, 2026: Ocular Therapeutix, Inc filed a report on a major company event (Form 8-K)
Get OCUL news as it happens
Every headline, SEC filing and analyst action for OCUL on your live chart, with important news marked and alerts when it matters.
Try SEPT Free